These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8390548)

  • 1. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children.
    Gruber WC; Kirschner K; Tollefson S; Thompson J; Reed G; Edwards KM; Wright PF
    J Infect Dis; 1993 Jul; 168(1):53-60. PubMed ID: 8390548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.
    Belshe RB; Swierkosz EM; Anderson EL; Newman FK; Nugent SL; Maassab HF
    J Infect Dis; 1992 Apr; 165(4):727-32. PubMed ID: 1552202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of institutionalized asthmatic children and patients with psychomotor retardation using live attenuated cold-adapted reassortment influenza A H1N1, H3N2 and B vaccines.
    Miyazaki C; Nakayama M; Tanaka Y; Kusuhara K; Okada K; Tokugawa K; Ueda K; Shibata R; Nishima S; Yamane N
    Vaccine; 1993; 11(8):853-8. PubMed ID: 8356846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
    Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.
    Nolan T; Lee MS; Cordova JM; Cho I; Walker RE; August MJ; Larson S; Coelingh KL; Mendelman PM
    Vaccine; 2003 Mar; 21(11-12):1224-31. PubMed ID: 12559802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.
    Zangwill KM; Droge J; Mendelman P; Marcy SM; Partridge S; Chiu CY; Jing J; Chang SJ; Cho I; Ward JI
    Pediatr Infect Dis J; 2001 Aug; 20(8):740-6. PubMed ID: 11734734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response.
    Gruber WC; Darden PM; Still JG; Lohr J; Reed G; Wright PF
    Vaccine; 1997; 15(12-13):1379-84. PubMed ID: 9302748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
    Gruber WC; Belshe RB; King JC; Treanor JJ; Piedra PA; Wright PF; Reed GW; Anderson E; Newman F
    J Infect Dis; 1996 Jun; 173(6):1313-9. PubMed ID: 8648202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children.
    King JC; Lagos R; Bernstein DI; Piedra PA; Kotloff K; Bryant M; Cho I; Belshe RB
    J Infect Dis; 1998 May; 177(5):1394-7. PubMed ID: 9593032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.
    Keitel WA; Couch RB; Quarles JM; Cate TR; Baxter B; Maassab HF
    J Infect Dis; 1993 Feb; 167(2):305-11. PubMed ID: 8421165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.
    Anderson EL; Newman FK; Maassab HF; Belshe RB
    J Clin Microbiol; 1992 Sep; 30(9):2230-4. PubMed ID: 1400985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets.
    Shen Z; Bowen RA; Ge P; Yu J; Shen Y; Kong W; Jiang C; Wu J; Zhu C; Xu Y; Wei W; Rudenko L; Kiseleva I; Xu F
    Vaccine; 2016 Nov; 34(48):5953-5958. PubMed ID: 27997342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.